METHOD FOR PREDICTION OF RECURRENCE-FREE SIRVIVAL IN CERVICAL CANCER BY CANCER TISSUE GLUTATHIONE REDUCTASE ACTIVITY TEST Russian patent published in 2013 - IPC G01N33/48 G01N33/50 

FIELD: medicine.

SUBSTANCE: patient with advanced cervical cancer (FIGO stage IIb-IV) is examined for tumor tissue glutathione reductase activity. When tumour tissue glutathione reductase activity is 10.9 to 14.9 mmol/min/mg of protein, the patient is expected to have 18% probability of the 18-month recurrence-free survival period, while tumour tissue glutathione reductase activity being 15.2 to 18.5 mmol/min/mg of protein shows 60% probability of the 18-month recurrence-free survival period.

EFFECT: use of the declared method enables predicting the recurrence-free survival period in local cervical cancer.

1 ex